Methyl 4-HydroxyphenylacetateCAS# 14199-15-6 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 14199-15-6 | SDF | Download SDF |
| PubChem ID | 518900 | Appearance | Cryst. |
| Formula | C9H10O3 | M.Wt | 166.2 |
| Type of Compound | Phenols | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | methyl 2-(4-hydroxyphenyl)acetate | ||
| SMILES | COC(=O)CC1=CC=C(C=C1)O | ||
| Standard InChIKey | XGDZEDRBLVIUMX-UHFFFAOYSA-N | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | 1. Methyl 4-Hydroxyphenylacetate has potent inhibitory activity against tobacco mosaic virus (TMV). |
| Targets | Antifection |
Methyl 4-Hydroxyphenylacetate Dilution Calculator
Methyl 4-Hydroxyphenylacetate Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 6.0168 mL | 30.0842 mL | 60.1685 mL | 120.3369 mL | 150.4212 mL |
| 5 mM | 1.2034 mL | 6.0168 mL | 12.0337 mL | 24.0674 mL | 30.0842 mL |
| 10 mM | 0.6017 mL | 3.0084 mL | 6.0168 mL | 12.0337 mL | 15.0421 mL |
| 50 mM | 0.1203 mL | 0.6017 mL | 1.2034 mL | 2.4067 mL | 3.0084 mL |
| 100 mM | 0.0602 mL | 0.3008 mL | 0.6017 mL | 1.2034 mL | 1.5042 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Emetine Hydrochloride
Catalog No.:BCN2478
CAS No.:14198-59-5
- 16-Hydroxycleroda-3,13-dien-15,16-olide
Catalog No.:BCN7500
CAS No.:141979-19-3
- 14-Deoxy-11,12-didehydroandrographiside
Catalog No.:BCN1572
CAS No.:141973-41-3
- Ginsenoside Rg3
Catalog No.:BCN1068
CAS No.:14197-60-5
- Ginsenoyne K
Catalog No.:BCN3953
CAS No.:141947-42-4
- Pimentol
Catalog No.:BCN2714
CAS No.:141913-95-3
- 4-Hydroxyphenylacetonitrile
Catalog No.:BCN6905
CAS No.:14191-95-8
- H-HoTyr-OH.HBr
Catalog No.:BCC3245
CAS No.:141899-12-9
- Fmoc-Cys(pMeOBzl)-OH
Catalog No.:BCC3477
CAS No.:141892-41-3
- Magnoloside D
Catalog No.:BCN8062
CAS No.:1418309-03-1
- EI1
Catalog No.:BCC4044
CAS No.:1418308-27-6
- Minaxin C
Catalog No.:BCN7656
CAS No.:1418150-06-7
- NSC 625987
Catalog No.:BCC7269
CAS No.:141992-47-4
- NVP-TNKS656
Catalog No.:BCC6541
CAS No.:1419949-20-4
- Caproic acid
Catalog No.:BCC9218
CAS No.:142-62-1
- BIM 189
Catalog No.:BCC5934
CAS No.:142062-55-3
- Isosalvianolic acid C
Catalog No.:BCN3476
CAS No.:142115-17-1
- WS 3
Catalog No.:BCC7519
CAS No.:1421227-52-2
- WS6
Catalog No.:BCC5566
CAS No.:1421227-53-3
- (+)-Ketoconazole
Catalog No.:BCC4249
CAS No.:142128-59-4
- CYM 50769
Catalog No.:BCC6337
CAS No.:1421365-63-0
- Mutated EGFR-IN-1
Catalog No.:BCC5444
CAS No.:1421372-66-8
- Mutant EGFR inhibitor
Catalog No.:BCC4119
CAS No.:1421373-62-7
- AZD-9291
Catalog No.:BCC4120
CAS No.:1421373-65-0
A novel and other bioactive secondary metabolites from a marine fungus Penicillium oxalicum 0312F1.[Pubmed:23962399]
Nat Prod Res. 2013;27(24):2286-91.
A new compound 2-(4-hydroxybenzoyl) quinazolin-4(3H)-one (1) and four known compounds were isolated from a marine fungus Penicillium oxalicum 0312F1. The structure of the new compound 1 was elucidated based on the spectroscopic analysis. Bioactivity assays showed that 2-(4-hydroxybenzyl) quinazolin-4(3H)-one (2) and Methyl 4-Hydroxyphenylacetate (5) had potent inhibitory activity against tobacco mosaic virus (TMV), and the new compound 1 had moderate inhibitory activity against TMV and human gastric cancer cell SGC-7901.
A simple, selective, and sensitive gas chromatography-mass spectrometry method for the analysis of five process-related impurities in atenolol bulk drug and capsule formulations.[Pubmed:28581679]
J Sep Sci. 2017 Aug;40(15):3086-3093.
An extremely sensitive and simple gas chromatography with mass spectrometry method was developed and completely validated for the analysis of five process-related impurities, viz., 4-hydroxy-l-phenylglycine, 4-hydroxyphenylacetonitrile, 4-hydroxyphenylacetic acid, methyl-4-hydroxyphenylacetate, and 2-[4-{(2RS)-2-hydroxy-3-[(1-methylethyl)amino]propoxy}phenyl]acetonitrile, in atenolol. The separation of impurities was accomplished on a BPX-5 column with dimensions of 50 m x 0.25 mm i.d. and 0.25 mum film thickness. The method validation was performed following International Conference on Harmonisation guidelines in which the method was capable to quantitate 4-hydroxy-l-phenylglycine, 4-hydroxyphenylacetonitrile, and 4-hydroxyphenylacetic acid at 0.3 ppm, and methyl-4-hydroxyphenylacetate and 2-[4-{(2RS)-2-hydroxy-3-[(1-methylethyl)amino]propoxy}phenyl]acetonitrile at 0.35 ppm with respect to 10 mg/mL of atenolol. The method was linear over the concentration range of 0.3-10 ppm for 4-hydroxy-l-phenylglycine, 4-hydroxyphenylacetonitrile, and 4-hydroxyphenylacetic acid, and 0.35-10 ppm for methyl-4-hydroxyphenylacetate and 2-[4-{(2RS)-2-hydroxy-3-[(1-methylethyl)amino]propoxy}phenyl]acetonitrile. The correlation coefficient in each case was found >/=0.998. The repeatability and recovery values were acceptable, and found between 89.38% and 105.60% for all five impurities under optimized operating conditions. The method developed here is simple, selective, and sensitive with apparently better resolution than the reported methods. Hence, the method is a straightforward and good quality control tool for the quantitation of selected impurities at trace concentrations in atenolol.
